Reason for request
Extension of indication
Clinical Benefit
| Substantial |
The actual benefit of CERUBIDINE 20 mg is substantial, as part of a combination chemotherapy regimen, in the treatment of acute lymphoblastic leukaemia and acute myeloblastic leukaemia in children. |
Clinical Added Value
| no clinical added value |
CERUBIDINE 20 mg does not provide any improvement in actual benefit (level V, non-existent) in the treatment of acute lymphoblastic and myeloblastic leukaemia in children. |
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
Y301EWsRb4hZ5nyy
